(https://www.cnbc.com/2026/06/17/huntingtons-disease-drugmaker-uniqure-to-seek-fda-ok-for-gene-therapy.html) after months of tension looks like a redemption story — but here's what's being missed. UTHR's CEO Martine Rothblatt sold $8.1M in stock on June 5th while the company was quietly preparing this announcement. That's not confidence in a clinical win. That's liquidity management ahead of volatility.

Research these companies